(±)-SLV319

    • 货号:MC1362
      • CasNo:
      • 362519-49-1
      • 分子式:
      • C23H20Cl2N4O2S
      • 纯度:
      • >98%
      • 靶点:
      • Cannabinoid Receptor
      • IC50:
      • IC50: 22 nM (CB-1)[1]; Ki: 7.8 nM (CB-1)[2]
      • 体外研究:
      • Cannabinoid receptor 1 (CB1R) antagonists appear to be promising drugs for the treatment of obesity, however, serious side effects have hampered their clinical application. Ibipinabant is a new, potent [Ki (CB1)=7.8 nM] and selective [Ki (CB2)=7.943 nM] CB1 antagonist [pA2 for arachidonic acid release in CHO cells=9.9] with in vitro pharmacological characteristics similar to rimonabant including inverse agonism and brain penetrance[3].
      • 体内研究:
      • Ibipinabant (3 mg/kg) reduces unfasted glucose to a significantly greater degree than rimonabant at the same dose on days 17, 28 and 38. Chronic treatment with ibipinabant significantly attenuates the progression of diabetes in ZDF rats, blunting the increase in blood glucose and HbA1c over time. Ibipinabant also reduces the hyperinsulinemia apparent at 6-8 weeks of age and attenuates the dramatic reduction in insulin levels observed 1-2 weeks later[3].
      • 简介:
      • (±)-SLV 319 is a potent and selective CB1 receptor antagonist (Ki = 7.8 nM). Exhibits 1000-fold selectivity for CB1 over CB2 receptors. IC50: 22 nM (CB-1)[1]; Ki: 7.8 nM (CB-1)[2]
      • 特异性:
      • Target: Cannabinoid Receptor. Fields: (±)-SLV 319 is a potent and selective CB1 receptor antagonist (Ki = 7.8 nM). Exhibits 1000-fold selectivity for CB1 over CB2 receptors. IC50: 22 nM (CB-1)[1]; Ki:
      • 来源:
      • Rabbit
      • 稀释:
      • IC50: 22 nM (CB-1)[1]; Ki: 7.8 nM (CB-1)[2]
      • 浓度:
      • >98%
      • 储存:
      • 2 years -20°C Powder, 2 weeks4°C in DMSO,6 months-80°C in DMSO
      • 其他名称:
      • SLV 319,SLV-319
      • 分子量:
      • 487.4
      • 产品图片